Why Ergothioneine Is the Longevity Antioxidant to Watch
Neil Tuckwell·· min read
Why Ergothioneine Is the Longevity Antioxidant to Watch
Among the dozens of compounds now studied in longevity research, ergothioneine (ET) stands out for a specific reason: humans have a dedicated, evolutionarily conserved transporter protein whose only known job is to absorb and retain it. Research now links declining blood levels of ET after age 60 to faster cognitive deterioration, higher cardiovascular mortality, and greater frailty risk. Understanding why this molecule behaves differently from conventional antioxidants, and what the human evidence actually shows, is the first step toward making an informed decision about whether an ergothioneine supplement belongs in a longevity protocol.
What Is Ergothioneine and Why Is It Different?
Ergothioneine is a histidine-derived, sulfur-containing amino acid produced exclusively by certain fungi and soil bacteria. Humans and most other mammals cannot synthesize it, which means dietary intake is the only source [6]. The primary routes of exposure are mushrooms (especially oyster, shiitake, and king trumpet varieties), organ meats such as kidney and liver, black and red beans, and some fermented foods. Most fruits, non-mushroom vegetables, and common grains contain negligible amounts [6, 8]. A typical Western diet provides an estimated 1 to 5 mg per day, and blood levels begin a measurable decline after age 60, tracking alongside other established longevity-associated biomarkers [6, 12].
What separates ET from most dietary antioxidants is not simply its potency but its biological infrastructure. The SLC22A4 gene encodes the OCTN1 transporter, a high-affinity protein expressed prominently in the gut epithelium, kidney tubules, erythrocytes, and immune cells [6, 10]. Once absorbed, ET is retained rather than rapidly excreted: the kidney actively reabsorbs it, allowing substantial accumulation in tissues including the liver, brain, and muscle. The existence of this dedicated, evolutionarily conserved uptake system is strong circumstantial evidence that ET performs a function specific enough to justify the metabolic cost of maintaining a dedicated importer [6].
A second structural distinction concerns oxidative chemistry. Most antioxidants, including ascorbate (vitamin C), can be oxidized to reactive intermediates that themselves cause cellular damage under certain conditions. ET's molecular architecture involves a thione/thiol tautomerism that prevents this pro-oxidant conversion, meaning it functions as a net cytoprotective agent even at higher intracellular concentrations . This property, combined with its ability to cross the blood-brain barrier, positions ET as a candidate for neuroprotection rather than a generic free-radical scavenger .
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
Related Articles
Longevity Science
Spermidine and Autophagy: The Ultimate 2026 Review
What does the research actually say about spermidine autophagy supplements? We break down 15 studies on dosing, safety, and real benefits.
The inability to synthesize ET, the dedicated transporter, the age-related decline, and the tissue-specific accumulation have prompted multiple research groups to propose that ET should be reclassified as a conditionally essential micronutrient rather than a merely beneficial dietary compound [6]. That proposal remains contested, but it signals a meaningful shift in how the scientific community is framing its relevance to healthy aging.
The Mechanism: How Ergothioneine Protects Cells
For decades, ET was characterized simply as an antioxidant. More recent research has identified a cascade of molecular actions that extend well beyond reactive oxygen species (ROS) scavenging. The most significant mechanistic advance came in 2025, when a proteome-wide thermal stability screen across more than 6,000 proteins in mouse tissue identified 3-mercaptopyruvate sulfurtransferase (MPST) as the first physiologically relevant direct molecular target of ET [11]. MPST activation by ET enhances mitochondrial respiration capacity, a finding that connects ET directly to the bioenergetic health of cells rather than simply their antioxidant defense [11].
A 2024 study provided the first direct evidence that ET accumulates within isolated mitochondria themselves, not merely in the cytoplasm surrounding them [10]. Mitochondria from OCTN1 knockout mice still showed residual ET uptake, suggesting at least one additional mitochondrial transporter may contribute, potentially SLC22A15 [10]. This mitochondrial concentration is significant because the electron transport chain is the cell's primary site of superoxide production, and having a stable, non-auto-oxidizing antioxidant concentrated precisely at that site represents a biologically rational defense strategy.
Beyond direct ROS suppression, ET activates the KEAP1-NRF2 signaling axis, a master regulator of the cellular antioxidant response [9]. NRF2 activation drives expression of superoxide dismutase and catalase, amplifying ET's protective effect through enzymatic pathways that persist after the molecule itself has been metabolized. ET also modulates three core aging-regulatory pathways: insulin/IGF-1 signaling (IIS), the SIRT6 deacetylase, and mTOR [7]. These intersections suggest that ET's influence on longevity may extend into epigenetic regulation and cellular senescence, not only oxidative stress management.
An additional mechanism involves H2S production. ET acts as an alternative substrate for cystathionine gamma-lyase, stimulating hydrogen sulfide generation that persulfidates over 300 downstream protein targets and raises intracellular NAD+ levels. Elevated NAD+ links ET to sirtuin activity and to the broader class of NAD+-dependent longevity mechanisms now receiving significant research attention. Taken together, these converging pathways mean that characterizing ET solely as an "antioxidant" may understate its functional scope within the aging biology literature.
What the Evidence Shows
The most compelling human data on ET comes from a 21-year prospective cohort study of 3,236 Swedish adults without baseline cardiovascular disease or diabetes [1]. Using liquid chromatography-mass spectrometry metabolomics, investigators measured plasma ET levels and tracked outcomes across a median follow-up of 21.4 years. Higher plasma ET was independently associated with a 15% reduction in coronary disease risk (hazard ratio 0.85, p=0.01), a 21% reduction in cardiovascular mortality (HR 0.79, p=0.002), and a 14% reduction in all-cause mortality (HR 0.86, p=4x10^-5) per one standard deviation increase in plasma concentration [1]. These associations held after multivariable adjustment including conventional cardiovascular risk factors.
The cognitive protection data are similarly consistent, though based primarily on observational designs. A cross-sectional study of 496 participants across Singapore memory clinics found that plasma ET concentrations were lowest in dementia patients relative to those with no cognitive impairment, with statistically significant differences (p<0.001) [2]. Lower ET was inversely correlated with white matter hyperintensities on neuroimaging, reduced cortical thickness, and diminished hippocampal volume — structural markers of neurodegeneration rather than performance-based tests alone [2]. A separate longitudinal cohort of 470 elderly clinic attendees found that lower baseline plasma ET predicted faster decline across six cognitive domains including memory, executive function, attention, visuomotor speed, and language (p<0.001) [3].
The first interventional data emerged from a double-blinded, randomized, placebo-controlled pilot trial in 19 adults aged 60 and above with mild cognitive impairment (MCI) [4]. Participants received 25 mg of ET three times per week for 52 weeks. The ET group showed improved performance on the Rey Auditory Verbal Learning Test and, critically, plasma neurofilament light chain (NfL) levels — a biomarker of neuronal injury — stabilized over the year while rising in the placebo group [4]. The sample size limits the conclusions that can be drawn, but the NfL finding is notable because it suggests a possible effect on the rate of neurodegeneration itself, not only on cognitive test scores. A 2025 narrative review synthesizing this body of evidence called for larger, long-term randomized controlled trials to establish causality and define optimal dosing protocols [12].
It is important to be precise about what the current evidence does and does not support. The prospective cohort data are strong for association but cannot establish causation; low ET may be a marker of unhealthy lifestyle or metabolic dysfunction rather than a causal factor in mortality. The interventional trials are small and pilot in design. No phase III RCT in cardiovascular or cognitive outcomes has been completed for an ergothioneine supplement. The mechanistic rationale is biologically coherent and the human biomarker data are consistent, but the field is still in an early stage of translating observations into actionable clinical recommendations.
Who Might Need Ergothioneine Most
The available evidence identifies several populations in whom plasma ET levels are characteristically low and in whom the downstream consequences may be most clinically significant. Adults over the age of 60 represent the broadest at-risk group, given the documented age-related decline in blood ET concentrations [6, 12]. This decline coincides with the period of life when cardiovascular risk, cognitive vulnerability, and frailty risk all escalate, making the temporal correlation biologically plausible even in the absence of established causality.
Individuals attending memory clinics or carrying risk factors for dementia represent a second population where the data are particularly direct [2, 3]. The magnitude of the plasma ET difference between cognitively intact older adults and those with established dementia in the Singapore cohort studies suggests that low ET is not a trivial finding in this context. Whether correcting a low ET level in someone at risk for cognitive decline would modify the trajectory is the central unanswered clinical question, but the biomarker pattern is consistent enough to warrant attention.
People who consume few or no mushrooms and limited organ meat may have chronically low dietary ET intake [6, 8]. Given that the Western diet is estimated to provide just 1 to 5 mg per day, and that plasma levels decline further with age, the intersection of low intake and reduced absorption efficiency in older adults could represent a meaningful gap. Individuals with functional variants in the SLC22A4 gene that reduce OCTN1 transporter activity may also have lower plasma ET independent of diet, though the clinical implications of these variants in otherwise healthy adults remain under investigation [6].
A fourth group worth noting is those with frailty or pre-frailty. Research indicates that declining ET tracks with cognitive but not skeletal muscle deterioration in frail elderly individuals, suggesting that the compound's relevance may be specifically neurocognitive rather than broadly physical [5]. This specificity, if confirmed in larger studies, would help refine which individuals are most likely to benefit from dietary or supplemental intervention.
Side Effects, Safety, and Dosage
The safety profile of ET at studied doses is reassuring, though the human trial database is limited in scale and duration. The pilot RCT that dosed 19 MCI participants with 25 mg three times per week for 52 weeks reported no adverse changes to blood counts, kidney function, or liver function over the full year of the study [4]. A 2025 synthesis of available interventional data confirmed that 25 mg per day represents the maximum tested dose in published human trials, with no adverse events reported at that level [12].
No clinically documented drug-drug or nutrient-nutrient interactions have been identified in the reviewed literature. A theoretical consideration exists around the OCTN1 transporter, which also handles carnitine transport; the possibility of competitive inhibition between ET and carnitine has not been studied in humans [6, 10]. Additionally, individuals taking carnitine supplements alongside an ergothioneine supplement at the same time may wish to raise this theoretical interaction with their healthcare provider, though no clinical evidence of an adverse interaction exists as of March 2026.
Research also suggests a potential synergistic or complementary relationship between ET and vitamin E in brain tissue protection, with the two compounds appearing to protect anatomically distinct regions of the brain [12]. This is a preliminary observation and does not constitute evidence that combining them is either necessary or harmful. The point underscores that ET operates within a broader nutritional context rather than as an isolated intervention.
No established optimal human supplementation dose exists as of 2026. The 25 mg per day threshold is the highest reported in published trials with confirmed safety, and it is the reference point most cited in recent reviews. The dietary contribution from regular mushroom consumption (estimated at 1 to 5 mg per day) appears to correlate with meaningful differences in plasma ET levels and cardiovascular outcomes in population studies [1, 6], but whether dietary intake alone can replicate the levels achieved with supplementation in older adults remains unclear. Long-term safety data beyond 12 months in humans has not yet been published, and individuals considering an ergothioneine supplement should discuss this with a qualified healthcare provider before starting.
Frequently Asked Questions
What foods are the best sources of ergothioneine?
Mushrooms are by far the richest dietary source of ergothioneine, with oyster, shiitake, and king trumpet varieties containing particularly high concentrations. Organ meats such as kidney and liver also provide meaningful amounts, as do black and red beans and certain fermented foods. Most fruits, non-mushroom vegetables, and common grains contain negligible ergothioneine, which means that people who eat few mushrooms and limited organ meat may have chronically low dietary exposure [6, 8].
Does ergothioneine actually cross into the brain?
Research indicates that ET does cross the blood-brain barrier, where it may exert neuroprotective effects through antioxidant activity, anti-inflammatory signaling, and support for neurotrophin levels [8]. Observational studies have found inverse correlations between plasma ET and structural markers of brain deterioration including white matter hyperintensities, cortical thinning, and reduced hippocampal volume [2]. Whether supplemental ET reaches sufficient concentrations in the human brain to produce clinically meaningful effects requires further investigation.
Is ergothioneine safe to take as a supplement?
At doses up to 25 mg per day, no adverse events have been reported in published human trials, including no changes to blood counts, kidney function, or liver markers over 12 months of use [4, 12]. However, the human trial database is small, and long-term safety data beyond one year is not yet available. An ergothioneine supplement should only be considered under the guidance of a healthcare provider, particularly for individuals taking other medications or with existing medical conditions.
Why do ergothioneine blood levels fall with age?
Plasma ergothioneine concentrations begin a measurable decline after age 60, a pattern documented in both cross-sectional and longitudinal data [6, 12]. The reasons are not fully characterized but likely reflect a combination of reduced dietary intake, age-related changes in gut absorptive function, and shifts in metabolic turnover. The decline parallels trajectories seen with other biomarkers of healthy aging, which is one reason researchers have proposed that maintaining adequate ET levels may be relevant to longevity outcomes.
How does ergothioneine compare to other antioxidant supplements?
ET occupies a distinct position among dietary antioxidants. Unlike ascorbate and glutathione, it does not convert to a pro-oxidant form under physiological conditions due to its thione/thiol tautomerism [8]. Unlike most antioxidants, it has a dedicated, high-affinity transporter that concentrates it inside cells and mitochondria [6, 10]. Among recently studied longevity compounds, ET is distinguished by the depth of human epidemiological data directly linking circulating levels to hard endpoints such as cardiovascular mortality and all-cause mortality over more than two decades of follow-up [1]. These features do not make it superior to all other antioxidants for all purposes, but they do define a biologically specific and evidence-grounded rationale for attention.
References
[1] Smith E et al. "Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease." Heart. 2020. DOI: 10.1136/heartjnl-2019-315485. PMID: 31672783.
[2] Wu LY et al. "Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia." Free Radical Biology and Medicine. 2021. DOI: 10.1016/j.freeradbiomed.2021.10.019. PMID: 34673145.
[3] Wu LY et al. "Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics." Antioxidants (Basel). 2022. DOI: 10.3390/antiox11091717. PMID: 36139790.
[4] Yau YF et al. "Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: A pilot study." Journal of Alzheimer's Disease. 2024. DOI: 10.1177/13872877241291253. PMID: 39544014.
[5] Kondoh H et al. "Decline of ergothioneine in frailty and cognition impairment." FEBS Letters. 2022. DOI: 10.1002/1873-3468.14299. PMID: 35090053.
[6] Tian X et al. "Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing?" British Journal of Nutrition. 2023. DOI: 10.1017/S0007114522003592. PMID: 38018890.
[7] Apparoo Y et al. "Ergothioneine and its prospects as an anti-ageing compound." Experimental Gerontology. 2022. DOI: 10.1016/j.exger.2022.111982. PMID: 36244584.
[8] Paul BD. "Ergothioneine: A Stress Vitamin with Antiaging, Vascular, and Neuroprotective Roles?" Antioxidants & Redox Signaling. 2022. DOI: 10.1089/ars.2021.0043. PMID: 34619979.
[9] Chen L et al. "Ergothioneine and its congeners: anti-ageing mechanisms and pharmacophore biosynthesis." Protein & Cell. 2024. DOI: 10.1093/procel/pwad048. PMID: 37561026.
[10] Fong ZW et al. "Ergothioneine and mitochondria: An important protective mechanism?" Biochemical and Biophysical Research Communications. 2024. DOI: 10.1016/j.bbrc.2024.150269. PMID: 38909533.
[11] Sprenger HG et al. "Ergothioneine controls mitochondrial function and exercise performance via direct activation of MPST." Cell Metabolism. 2025. DOI: 10.1016/j.cmet.2025.01.024. PMID: 39965563.
[12] May-Zhang LS et al. "Ergothioneine for cognitive health, longevity and healthy ageing: where are we now?" Proceedings of the Nutrition Society. 2025. DOI: 10.1017/S0029665125101754. PMID: 40968729.
This content is for informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any supplement or making changes to your health regimen.
